| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1191/0961203305LU2220OA |
| P698 | PubMed publication ID | 16218487 |
| P50 | author | Piercarlo Sarzi-Puttini | Q30002194 |
| Andrea Doria | Q38544117 | ||
| P2093 | author name string | F Atzeni | |
| M Turiel | |||
| L Iaccarino | |||
| P2860 | cites work | Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy | Q30479528 |
| An overview of tumor necrosis factor alpha and the failing human heart. | Q33652558 | ||
| Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart | Q33907789 | ||
| Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 | ||
| Tumour necrosis factor alpha: a key regulator of adipose tissue mass | Q35139281 | ||
| Tumour necrosis factor-alpha and the failing heart--pathophysiology and therapeutic implications | Q35611462 | ||
| Is there any future for tumor necrosis factor antagonists in chronic heart failure? | Q35668974 | ||
| Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy | Q35676074 | ||
| Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? | Q35743195 | ||
| Adalimumab therapy in rheumatoid arthritis | Q35789083 | ||
| Future prospects of anticytokine therapy in chronic heart failure | Q36087238 | ||
| TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma | Q36095168 | ||
| Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression | Q37242403 | ||
| Cardiac interstitium in health and disease: the fibrillar collagen network | Q38633516 | ||
| Complement activation and inhibition in myocardial ischemia and reperfusion injury | Q40678974 | ||
| The tumor necrosis factor ligand and receptor families. | Q40990575 | ||
| Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis | Q43049221 | ||
| Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection | Q44022447 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. | Q44651976 | ||
| Treatment of rheumatoid arthritis in the third millennium | Q45153959 | ||
| Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu | Q47849023 | ||
| Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure. VEST Investigators for TNF Genotype Analysis. Vesnarinone Survival Trial | Q47870923 | ||
| Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). | Q47945239 | ||
| Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure | Q48034134 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 780-784 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | Lupus | Q6704846 |
| P1476 | title | Tumor necrosis factor-alpha, biologic agents and cardiovascular risk | |
| P478 | volume | 14 |
| Q36979267 | A molecular mechanism for TNF-α-mediated downregulation of B cell responses |
| Q36461116 | Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus |
| Q47116886 | Adipose Tissue Inflammation Induces B Cell Inflammation and Decreases B Cell Function in Aging |
| Q35806803 | Aging impairs murine B cell differentiation and function in primary and secondary lymphoid tissues |
| Q36684042 | Anti-tumour necrosis factor-alpha therapy in heart failure: future directions |
| Q38876331 | Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment. |
| Q28395077 | Chemical constituents of ambient particulate air pollution and biomarkers of inflammation, coagulation and homocysteine in healthy adults: a prospective panel study |
| Q37300823 | Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis |
| Q90694588 | Corylin Inhibits Vascular Cell Inflammation, Proliferation and Migration and Reduces Atherosclerosis in ApoE-Deficient Mice |
| Q37707181 | High TNF-α levels in resting B cells negatively correlate with their response |
| Q55315794 | How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms? |
| Q36225887 | Inflammaging decreases adaptive and innate immune responses in mice and humans |
| Q46034422 | Inflammatory mediators in Chinese patients with congestive heart failure. |
| Q39524774 | Medial Expression of TNF-α and TNF Receptors Precedes the Development of Atherosclerotic Lesions in Apolipoprotein E/LDL Receptor Double Knockout Mice |
| Q91742867 | Metabolic requirements of human pro-inflammatory B cells in aging and obesity |
| Q92063931 | Personal Fine Particulate Matter Constituents, Increased Systemic Inflammation, and the Role of DNA Hypomethylation |
| Q39421902 | Senescent B cells in aging and age-related diseases: Their role in the regulation of antibody responses |
| Q33400786 | TNFalpha-induced macrophage death via caspase-dependent and independent pathways |
| Q38293366 | Vitamin D and systemic lupus erythematosus: continued evolution |
Search more.